Clinical stage drug development company Telik, Inc. (TELK: Quote) posted second-quarter net loss of $2.1 million or $1.11 per share, narrower than $3.0 million or $1.67 per share in the previous year quarter.
Loss from operations narrowed to $2.06 million from $3.01 million in the comparable quarter last year.
Click here to receive FREE breaking news email alerts for TELIK INC and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com